ARTICLE | Clinical News
Endotoxin Activity Assay regulatory update
June 23, 2003 7:00 AM UTC
The FDA granted final marketing clearance for SDI's EAA severe sepsis risk test. Earlier this year, FDA said the test qualified for marketing clearance under the de novo process, which is a regulatory...